Download PDF
Thromb Haemost 1981; 46(04): 757-758
DOI: 10.1055/s-0038-1653470
Original Article
Schattauer GmbH Stuttgart

Delayed Elimination of Fibrin from the Lungs in Rats Given α2-Antiplasmin

G Carlin
The Institute of Forensic Medicine, University of Uppsala, Sweden and Kabi/Vitrum AB, Stockholm, Sweden
,
M Einarsson
The Institute of Forensic Medicine, University of Uppsala, Sweden and Kabi/Vitrum AB, Stockholm, Sweden
,
T Saldeen
The Institute of Forensic Medicine, University of Uppsala, Sweden and Kabi/Vitrum AB, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Received 09 October 1981

Accepted 02 November 1981

Publication Date:
05 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Injection of human α2–antiplasmin resulted in delayed elimination of fibrin from the lungs in rats with thrombin–induced intravascular coagulation. The amount of α2–antiplasmin injected was chosen so as to simulate the posttraumatic increase of this inhibitor in man. By injecting trace amounts only of radiolabelled α2–antiplasmin a specific uptake of this protein in the lungs was noted after the thrombin-induced coagulation. The results may indicate that the posttraumatic increase in α2–antiplasmin is of significance for the delayed elimination of fibrin seen in patients following trauma.

Keywords

α2–antiplasmin - Adult respiratory distress syndrome - Fibrinolysis in vivo
 

  • References

  • 1 Busch C, Dahlgren S, Jakobsson S, Jung B, Modig J, Saldeen T. The use of125I-labelled fibrinogen for determination of fibrin trapping in the lungs in patients developing the microembolism syndrome. Acta Anaesthesiol Scand 1975; Suppl 57: 46-54
    PubMedGoogle Scholar
  • 2 Saldeen T. The microembolism syndrome. Microvasc Res 1976; 11: 227-259
    CrossrefPubMedGoogle Scholar
  • 3 Saldeen T. The microembolism syndrome. In: The Microembolism Syndrome. Publ: Almqvist & Wiksell Int; Stockholm: 1979: 7-44
    Google Scholar
  • 4 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
    PubMedGoogle Scholar
  • 5 Bagge L, Saldeen T. The primary fibrinolysis inhibitor and trauma. Thromb Res 1978; 13: 1131-1136
    CrossrefPubMedGoogle Scholar
  • 6 Bagge L, Rammer L, Saldeen T. Experimental study of the importance of plasminogen activation inhibition for decreased elimination of intravascular fibrin after trauma. Forensic Sd 1973; 2: 54-55
    PubMedGoogle Scholar
  • 7 Wiman B, Collen D. Purification and characterisation of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem 1977; 78: 19-26
    CrossrefPubMedGoogle Scholar
  • 8 Busch C, Rammer L, Saldeen T. Quantitation of fibrin deposition and elimination in organs of rats injected with labelled fibrinogen and albumin. Thrombos Diathes haemorrh 1973; 29: 94-107
    PubMedGoogle Scholar
  • 9 Nilsson IM, Olow B. Determination of fibrinogen and fibrinogenolytic activity. Thrombos Diathes haemorrh 1962; 8: 297-310
    PubMedGoogle Scholar
  • 10 Carlin G, Modig J, Saldeen T. Effect of infusion of dextran 70 on fibrinolysis inhibition activity in human serum. Acta Chir Scand 1979; 145: 129-131
    PubMedGoogle Scholar
  • 11 Hogstorp H, Jacobsson H, Saldeen T. Effect of hepatectomy on the posttraumatic fibrinolysis inhibition and the primary fibrinolysis inhibitor in the rat. Thromb Res 1980; 18: 361-368
    CrossrefPubMedGoogle Scholar
  • 12 Koie K, Kamiya T, Ogata K, Takamatsu J. α2-plasmin-inhibitor defidency (Miyasato disease). Lancet 23.12.1978; 1334-1336
    PubMedGoogle Scholar